Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, State Key Laboratory for Digestive Health, National Clinical Research Center for Digestive Disease, Beijing ...

SPH-4336 is under clinical development by Shanghai Pharmaceutical Group and currently in Phase II for Dedifferentiated Liposarcoma. According to GlobalData, Phase II drugs for Dedifferentiated ...

Background: Dedifferentiated liposarcoma (DDLPS) is a rare mesenchymal cancer originating from the adipose tissue, with poor survival rates for most patients, highlighting the critical need for novel ...

The FDA has granted a breakthrough therapy designation (BTD) to letetresgene autoleucel (lete-cel) for the treatment of patients with unresectable or metastatic myxoid/round cell liposarcoma (MRCLS).